Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP

American Journal of Clinical Pathology

Volumn 125, Issue 4, 2006, Pages 592-597

  Darabi, Kamran ^a,b   Berg, Anders H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoimmune; Rituximab; Therapeutic apheresis; Thrombotic thrombocytopenic purpura

Indexed keywords

AUTOANTIBODY; METALLOPROTEINASE; METHYLPREDNISOLONE SODIUM SUCCINATE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CASE REPORT; CLINICAL FEATURE; COOMBS TEST; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PHYSICAL EXAMINATION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 33645549929     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/RLNMJ01WBJRNLH03     Document Type: Article

References (14)

1. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059-41063.
2. Allford S, Machin S. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120:556-573.
3. Zheng X, Pallerma AM, Goodnough LT, et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann intern Med. 2003;138:105-108.
4. Chemnitz J, Draube A, Scheid C, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105-108.
5. Gutterman L. Rituximab therapy for refractory TTP. Blood Cell Mol Dis. 2002;28:385-391.
6. Tsai H. Rituximab induces remission of cerebral ischemia caused by TTP. Eur J Haematol. 2003;70:183-185.
7. Sallah S, Husain A, Wan JY, et al. Rituximab in patients with refractory thrombotic thrombocytopenic purpura [letter]. J Thromb Haemost. 2004;2:834-836.
8. Yomtovian R. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124:787-795.
9. Gerritsen HE, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82:1386-1389.
10. Barlogie B, McLaughlin P, Alexanian R. Characterization of hematologic malignancies by flow cytometry. Anal Quant Cytol Histol. 1987;9:147-155.
11. Rituxan (rituximab). Available at http://www.rituxan.com/rituxan/pi/ #pharmacology. Accessed February 6, 2006.
12. Maloney D, Grillo-Lopez A, White C. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;6:2188-2195.
13. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280-3288.
14. Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28.